High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Conditions
- Acute Leukemia
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Graft Versus Host Disease
- Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Secondary Myelodysplastic Syndrome
Interventions
- DRUG: Busulfan
- DRUG: Cyclophosphamide
- DRUG: Fludarabine Phosphate
- PROCEDURE: Hematopoietic Cell Transplantation
- OTHER: Laboratory Biomarker Analysis
- DRUG: Melphalan Hydrochloride
- DRUG: Mycophenolate Mofetil
- PROCEDURE: Peripheral Blood Stem Cell Transplantation
- OTHER: Quality-of-Life Assessment
- DRUG: Tacrolimus
- RADIATION: Total-Body Irradiation
Sponsor
City of Hope Medical Center
Collaborators